Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.1 Primary Research
4.2 Secondary Research
4.3 Market Size Estimation
4.4 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 The increasing prevalence of epilepsy and glaucoma
5.2.2 Rising research and development funding for rare diseases
5.2.3 Increasing focus on players towards Sturge-weber syndrome
5.3 Restraints
5.3.1 Side effects of therapeutic drugs
5.4 Opportunities
5.4.1 Rising demand for non-invasive treatment generating requirement for laser therapy
5.5 Macroeconomic Indicators
6 Market Factor Analysis
6.1 Supply Chain Analysis
6.1.1 R&D
6.1.2 Parts Manufacturing
6.1.3 Distribution
6.1.4 Marketing & Sales
6.1.5 Post-Sales Monitoring
6.2 Demand & Supply: Gap Analysis
6.3 Pricing Analysis
6.4 Investment Opportunities
6.5 Porter's Five Forces Model
6.5.1 Bargaining Power of Suppliers
6.5.2 Bargaining Power of Buyers
6.5.3 Threat of New Entrants
6.5.4 Threat of Substitutes
6.5.5 Intensity of Rivalry
7 Global Sturge-Weber Syndrome Market, by Type
7.1 Overview
7.1.1 Type 1
7.1.2 Type 2
7.1.3 Type 3
8 Global Sturge-Weber Syndrome Market, by Diagnosis & Treatment
8.1 Overview
8.1.1 Treatment
8.1.2 Diagnosis
9 Global Sturge-Weber Syndrome Market, By End-User
9.1 Overview
9.1.1 Hospital & Clinics
9.1.2 Diagnostic Centre
10 Sturge-Weber Syndrome Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East and Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Company Market Share Analysis
11.1.1 Introduction
11.2 Competitive Landscape
11.2.1 Introduction
11.3 Key Developments
12 Company Profiles
12.1 Abbott
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products Offerings
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategy
12.2 Pfizer Inc.
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products Offerings
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.2.6 Key Strategy
12.3 F. Hoffmann-La Roche AG
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products Offerings
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.3.6 Key Strategy
12.4 Novartis AG
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products Offerings
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategy
12.5 UCB S.A.
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products Offerings
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategy
12.6 Sanofi
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products Offerings
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategy
12.7 Shire
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products Offerings
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategy
12.8 Aleva Neurotherapeutics SA
12.8.1 Company Overview
12.8.2 Products Offering
12.8.3 Key Developments
12.8.4 SWOT Analysis
12.8.5 Key Strategy
12.9 GW Pharmaceuticals, plc.
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products Offerings
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategy
12.1 ElectroCore LLC
12.10.1 Company Overview
12.10.2 Products Offerings
12.10.3 Key Developments
12.10.4 SWOT Analysis
12.10.5 Key Strategy
12.11 Johnson & Johnson
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products Offerings
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategy
13 Appendix
13.1 Discussion Blue Print
13.2 References